A Third Shot at EGFR: New Opportunities in Cancer Therapy
- PMID: 31706618
- DOI: 10.1016/j.tips.2019.10.004
A Third Shot at EGFR: New Opportunities in Cancer Therapy
Abstract
Epidermal growth factor receptor (EGFR) inhibitors were among the first type of targeted agents discovered in cancer and currently constitute the standard of care for a wide range of lung and colon malignancies. However, the therapeutic progress achieved with these drugs has been accompanied by the identification of an ever-increasing number of acquired resistance mechanisms that inevitably appear in nearly all patients. Increased knowledge on EGFR biochemistry, cellular crosstalk, and resistance pathways provides an opportunity to establish effective combination therapies and discover novel-acting inhibitors that prevent or overcome therapeutic resistance. One such strategy is the selective blockade of circulating growth factors such as EGF. In this review, we address the uses and limitations of approved EGFR inhibitors and explore the potential of drug combinations and new third avenues to block the activation of the EGFR.
Keywords: EGF inhibitors; EGFR; biological drugs; drug resistance; oncology; targeted drugs.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.Int J Mol Sci. 2017 Nov 15;18(11):2420. doi: 10.3390/ijms18112420. Int J Mol Sci. 2017. PMID: 29140271 Free PMC article. Review.
-
The quest to overcome resistance to EGFR-targeted therapies in cancer.Nat Med. 2013 Nov;19(11):1389-400. doi: 10.1038/nm.3388. Epub 2013 Nov 7. Nat Med. 2013. PMID: 24202392 Free PMC article. Review.
-
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.Pharmacol Res. 2019 Jan;139:395-411. doi: 10.1016/j.phrs.2018.11.014. Epub 2018 Nov 27. Pharmacol Res. 2019. PMID: 30500458 Review.
-
Emerging paradigms and recent progress in targeting ErbB in cancers.Trends Pharmacol Sci. 2024 Jun;45(6):552-576. doi: 10.1016/j.tips.2024.04.009. Epub 2024 May 25. Trends Pharmacol Sci. 2024. PMID: 38797570 Review.
-
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy.Ann Oncol. 2006 Jun;17 Suppl 7:vii109-14. doi: 10.1093/annonc/mdl962. Ann Oncol. 2006. PMID: 16760272 Review.
Cited by
-
Synthesis and Biological Evaluation of Novel Cationic Rhenium and Technetium-99m Complexes Bearing Quinazoline Derivative for Epidermal Growth Factor Receptor Targeting.Pharmaceutics. 2024 Sep 16;16(9):1213. doi: 10.3390/pharmaceutics16091213. Pharmaceutics. 2024. PMID: 39339249 Free PMC article.
-
Evaluation of Cytotoxicity and Metabolic Profiling of Synechocystis sp. Extract Encapsulated in Nano-Liposomes and Nano-Niosomes Using LC-MS, Complemented by Molecular Docking Studies.Biology (Basel). 2024 Jul 31;13(8):581. doi: 10.3390/biology13080581. Biology (Basel). 2024. PMID: 39194519 Free PMC article.
-
Identification of potential inhibitors for drug-resistant EGFR mutations in non-small cell lung cancer using whole exome sequencing data.Front Pharmacol. 2024 Jul 25;15:1428158. doi: 10.3389/fphar.2024.1428158. eCollection 2024. Front Pharmacol. 2024. PMID: 39130636 Free PMC article.
-
Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.Transl Lung Cancer Res. 2024 Jul 30;13(7):1649-1659. doi: 10.21037/tlcr-24-243. Epub 2024 Jul 23. Transl Lung Cancer Res. 2024. PMID: 39118879 Free PMC article.
-
Targeting cytokine and chemokine signaling pathways for cancer therapy.Signal Transduct Target Ther. 2024 Jul 22;9(1):176. doi: 10.1038/s41392-024-01868-3. Signal Transduct Target Ther. 2024. PMID: 39034318 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
